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Cyclosporine Measurement by FPIA, PC-RIA, and HPLC Following 
Liver Transplantation 
G.J. Burckart, A. Jain, W. Diven, R. Venkataramanan, and T.E. Starzl 
CYCLOSPORINE (CyA) monitoring of blood or plasma drug concentrations remains an important 
part of the use of this agent following organ transplanta-
tion. When CyA is used as the primary immunosuppres-
sant agent following liver transplantation (LT), monitoring 
becomes particularly important because of the altered 
pharmacokinetics of CyA in this patient population. Pre-
vious studies have demonstrated that wide variability 
exists in the fraction of the dose absorbed and in the 
clearance of Cy A in L T patients. I Clinical situations that 
exacerbate the poor absorption of Cy A are frequently 
present in L T patients and include cholestasis and biliary 
diversion through a T-tube. Monitoring CyA concentra-
tions in blood or plasma is also critically important when 
making the transition from intravenous to orallherapy in 
L T patients. 
Patient monitoring using a polycionaJ RIA (PC-RIA) kit 
for Cy A has been extensively evaluated in organ transplant 
patients. and its use in comparison to high-performance 
liquid chromatography (HPLC) in L T patients has been 
assessed. 2 Since the PC-RIA cross-reacts with metabolites 
of Cy A that are present in plasma or blood. its results are 
affected by a number of factors. Hepatic function in a LT 
patient will determine CyA metabolism and clearance. and 
biliary function affects the appearance of metabolites in 
blood and plasma. Early studies indicated that the initial 
two postoperative weeks following L T were the period of 
greatest discrepancy between the PC-RIA and HPLC 
assay results. with the PC-RIA occasionally being 10 times 
the HPLC concentration. 3 Later studies demonstrated that 
whole blood (WB) samples from L T patients contain 
amounts of M 17 and other Cy A metabolites that are in 
excess of concentrations observed in other transplant 
populations.· Other factors which may affect the ratio of 
PC-RIA results to HPLC CyA results include: the liming 
of the blood sample during the dosing interval since the 
PC-RIA/HPLC ratio is constantly changing. the absolute 
CyA concentration since higher levels result in better 
agreement between the PC-RIA and HPLC assays. and 
drug interactions. 
More recently another immunoassay technique has been 
developed for Cy A calIed fluorescence polarization immu-
noassay (FPIA). This technique is rapid to perform. but 
also uses a polyclonal antibody which is distinct from the 
PC-RIA. The objective of this study was to assess the 
factors affecting the FPIA technique in L T patients using 
comparisons to the PC-RIA and HPLC assays in blood and 
plasma. 
MATERIALS AND METHODS 
The FPIA assay was assessed in three separate ways. The first 
method involved making a comparison of the FPIA. PC-RIA. and 
HPLC assays on blood and plasma trough samples obtained on 
consecutive days from L T patients. Patients were included if 
samples could be obtained for the first 14 postoperative days 
following transplantation. The results of these assays on blood 
and plasma were compared to the other assays and to the 
biochemical profile which included blood urea nitrogen. serum 
creatinine, alkaline phosphatase. GGTP. ALT. AST, total and 
direct bilirubin, hematocrit, and albumin and total protein. 
The second method of assessment included the review of the 
clinical course of 50 L T patients who were monitored by daily 
assessment of WB FPL ... CyA concentration. Changes in blood 
concentration in relation to major clinical events and in relation to 
other drug therapy were noted. The third method of assessment 
included the FPIA analysis of plasma samples from LT patients 
not receiving Cy A in an effort to investigate the cross-reactivity of 
the assay with any endogenous or exogenous substfllte present in 
the plasma of an L T patient. 
The HPLC assays utilized cyclosporin D as an internal standard 
and followed the procedure previously described. 5 The PC-RIA 
assay (Sandoz. East Hanover, NJ) and the FPIA assay (Abbott 
Laboratories, Diagnostics Division. Irving, TX) were utilized as 
per manufacturers' directions. 
Stepwise multiple linear regression analysis (SAS Institute Inc. 
Cary. NC) was utilized to identify the biochemical factors tbat 
primarily influenced Cy_" concentrations measured by the FPIA 
assay. 
RESULTS 
Eleven L T patients were followed for the first 14 postop-
erative days using FPIA. PC-RIA. and HPLC measure-
ments on blood and plasma. Serum creatinine did not 
exceed 2.8 mg/dL in any of these patients during the 
two-week study period. Five of the I J patients received 
additional corticosteroids during the study period. The 
highest quantitative values for Cy A concentrations were 
recorded for the FPIA assay on WB. followed by either the 
PC·RIA result in whole blood or the TDX assay result 
from plasma. 
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In the regression analysis. 20% ofthe variability in FPIA 
plasma Cy A concentrations was related to the direct 
serum bilirubin concentration. Forty-eight percent of the 
variability in the FPIA/HPLC ratio was also related to 
serum bilirubin. As suggested by the regression analysis, 
the FPIA results were most disparate with the PC-RIA and 
the HPLC results when the serum bilirubin was elevated. 
Fig 1 demonstrates the manner in which the FPIA-mea-
sured Cy A plasma concentration appears to follow the 
serum bilirubin concentration while consistent results 
were obtained using the PC-RIA and HPLC assays. Dur· 
ing these periods of hyperbilirubinemia, the peak FPIAJ 
HPLC ratio in plasma exceeded 40: I in one patient. was 
30-40: I in two patients. and was between 20-30: I in an 
additional two patients. 
Figure 2 also includes the WB PC-RIA and FPIA. and 
demonstrates that assay differences in CyA measurement 
are not as striking with WB. Table llists the percentage of 
samples analyzed that had varying ratios of FPIA to 
PC-RIA measured CyA concentration. While the majority 
of WB samples had reasonable agreement between the 
PC·RIA and FPIA assays, over 75% of plasma samples 
had an FPIA to PC·RIA ratio of 1.5 to 3.5 times. 
Considerable variability in measured CyA concentra· 
tions were observed for the 50 L T patients followed with 
daily FPIA WB concentrations. Day-ta-day variations in 
measured trough concentrations were frequently 300 to 
600 ng/mL, necessitating daily patient sampling for CyA 
blood concentrations to determine a trend in concentration 
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Fig 1. Serum bilirubin and plasma CyA concentrations over the 
14-day postoperative period in patient 1 . For the lower figure: • = 
FPfA, 0 = PC·RIA, and • = HPLC. 
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fig 2. Serum bilirubin, WB, and plasma CyA concentrations by 
FPIA and PC·RIA over the 14~ay postoperative period in patient 
11. For the CyA concentration figures: • = FPtA and 0 = 
PC·RIA. 
changes. As previously documented with other assay 
techniques. dramatic changes in FPIA·assayed eyA blood 
concentrations frequently accompanied clamping the T· 
tube with return of bile to the small bowel. No clear 
association between FPIA-measured CyA levels and biop-
sy-proven rejection could be ascertained. with the occa-
sional occurrence of mild to moderate rejection in patients 
with blood concentrations in the accepted 800 to 1200 
ng/mL therapeutic blood concentration range. The FPIA 
assay did clearly demonstrate the effect of diltiazem to 
increase CyA concentrations, occasionally to twice the 
pre·diltiazem level. 
Another drug interaction which has been reported using 
the PC·RIA to measure CyA was also detectable using the 
FPIA assay. A bolus of methylprednisolone. which was 
usually I g intravenously, frequently increased the FPIA 
blood concentration of Cy A. Previous report of this inter-
action has theorized that methylprednisolone is inhibiting 
the metabolism of CyA.6 but HPLC studies have not 
Table 1. Ratio of FPlA to PC-RIA CyA..,."... In 
PlumaandWB 
FPIA/PC-RIA 
Pen:enlage 01 Resulls Wihn Rallo Range 
Ratio <1.5 1.5-2.5 25-3.5 
Whole blood 53.4"10 45.4% 1.2% 
Plasma 11.5% 50.7% 28.4"4 
>3.5 
9.2"10 
CyA MEASUREMENT BY FPlA. PC-RIA, AND HPLC 
demonstrated that change.7 Intravenous corticosteroids 
may produce a redistribution or compete for biliary elim-
ination of Cy A metabolites. thereby increasing metabolites 
in blood that are detected by the immunoassays. 
The studies of serum concentrations of Cy A by FPIA in 
patients not receiving CyA provided additional informa-
tion on the high levels observed in patients with hyperbil-
irubinemia. Twenty-six plasma samples were analyzed 
from 13 patients who underwent orthotopic liver transplan-
tation and who were not receiving Cy A at the time of the 
study. The highest concentration measured by FPIA in 
plasma was 148 ng/mL in a patient with a direct bilirubin 
of 18.3 mg/dL and in whom CyA had been discontinued 8 
days earlier. Only 8 of the 26 samples had concentrations 
above 50 ng/mL in plasma; in each case, the patient had 
received CyA 4 to IS days prior to obtaining the plasma 
sample. One patient had a serum direct bilirubin of 34.6 
mg/dL and yet did not have any CyA detected by FPIA. 
Six plasma samples from 6 patients with cirrhosis who 
were being evaluated for LT were also analyzed; all 6 
samples were assayed by FPIA as having less than 30 
ng/mL CyA. 
DISCUSSION 
Cy A measurement on the blood or plasma of LT patients 
is complicated by the presence of high concentrations of a 
large number of metabolites. Our studies of Cy A metabo-
lites in WB samples from various transplant populations 
have concentrated on the most lipid-soluble and pharma-
cologically active8 compounds such as MI7, MI. M18. and 
M21. These metabolites are found primarily within red 
blood cens. Little quantitative information on the more 
polar di- and trihydroxylated CyA metabolites has been 
performed. The present study suggests that these polar 
metabolites may inftuence assay results for Cy A using 
polyclonal antibody immunoassay techniques. 
The FPIA assay for CyA produces results that are 
approximately double that of the PC-RIA in half of the 
samples analyzed from LT patients. Parallel changes in the 
FPIA results in relation to the PC-RIA assay would allow 
the use of this assay in the L T population since experience 
with CyA monitoring with the PC-RIA is extensive. We 
have observed that increases in the FPIA assay are how-
ever disproportionate with other assays when hepatic 
function is compromised through immunologic rejection or 
through technical complications. The results of the plasma 
studies in patients not receiving Cy A confirmed two 
points: (I) that bilirubin alone has little inftuence on the 
FPIA assay as stated by the manufacturer and (2) assay 
variability results in the oc:casional detection of amounts of 
Cy A in plasma by FPIA when the patient is not receiving 
the drug. Therefore, the most reasonable explanation for 
the increased FPIA concentrations during hyperbil-
irubinemia is that Cy A metabolites accumulate in plasma 
and blood and cross-reaa with the FPIA to a greater 
extent than with the PC-RIA assay. The observation that 
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plasma FPIA concentrations appear to be disproponion-
ately inftuenced by hepatic dysfunction in relation to blood 
CyA concentrations suggests that the FPIA assay is more 
cross-reactive with the polar Cy A metabolites than is the 
PC-RIA. 
The clinical observations with the use of the FPIA Cy A 
assay in monitoring L T patients demonstrate the useful-
ness of this analytical technique for patient monitoring 
when a kinetic assessment of Cy A therapy is not required. 
Changes in FPIA whole blood concentrations were ob-
served following T -tube clamping, during transition from 
intravenous to oral therapy. and in relation to other drug 
administration. such as methyl prednisolone 1 and dil-
tiazem.9 as would be expected using other assay meth-
ods. 10 The day-to-day variability in trough WB CyA level 
measured by FPIA must be considered when monitoring 
an L T patient so that abrupt changes in therapy are not 
based upon single trough CyA observations. The dispro-
portionate change in the FPIA assay in relation to the 
PC-RIA during hyperbilirubinemia also demands ftexibility 
in what is accepted as the therapeutic range of Cy A 
concentrations in WB. For example. trough CyA concen-
trations in L T patients were commonly observed in excess 
of the 800 to 1200 ng/mL therapeutic range, and yet were 
not associated with CyA-induced renal dysfunction in the 
population reviewed. 
SUMMARY 
The factors affecting Cy A dosing and kinetics in L T 
patients are complex. and have been thoroughly investi-
gated and reviewed. II Plasma or WB CyA concentration 
monitoring remains the best method presently available for 
adjusting CyA dosage in LT patients in a timely manner. 
The availability of an FPIA assay for CyA has produced 
rapid drug analysis for transplant patient monitoring, but 
adds additional factors that must be considered in inter-
preting Cy A concentrations. Liver dysfunction may dis-
proportionately elevate Cy A plasma or blood levels when 
analyzed by FPIA in relation to PC-RIA or HPLC, and 
adjustment of the therapeutic range or analysis by a more 
specific assay method may be necessary for dosage adjust-
ment in these patients. The availability of a more specific 
antibody in an FPIA assay may avert these problems. as 
would the development of immunologic monitoring tech-
niques that provide a global assessment of immune sup-
pression produced by increasingly complex immunosup-
pressive regimens in LT patients. 
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